title: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
abstract: Anticancer cytotoxic agents go through a process by which their antitumor activity-on the basis of the amount of tumor shrinkage they could generate-has been investigated. In the late 1970s, the International Union Against Cancer and the World Health Organization introduced specific criteria for the codification of tumor response evaluation. In 1994, several organizations involved in clinical research combined forces to tackle the review of these criteria on the basis of the experience and knowledge acquired since then. After several years of intensive discussions, a new set of guidelines is ready that will supersede the former criteria. In parallel to this initiative, one of the participating groups developed a model by which response rates could be derived from unidimensional measurement of tumor lesions instead of the usual bidimensional approach. This new concept has been largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines. This special article also provides some philosophic background to clarify the various purposes of response evaluation. It proposes a model by which a combined assessment of all existing lesions, characterized by target lesions (to be measured) and nontarget lesions, is used to extrapolate an overall response to treatment. Methods of assessing tumor lesions are better codified, briefly within the guidelines and in more detail in Appendix I. All other aspects of response evaluation have been discussed, reviewed, and amended whenever appropriate.
authors.affiliation: European Organization for Research and Treatment of Cancer, Brussels, Belgium. pth@eortc.be
authors.forename: P
authors.initials: P
authors.lastname: Therasse
authors.forename: S G
authors.initials: SG
authors.lastname: Arbuck
authors.forename: E A
authors.initials: EA
authors.lastname: Eisenhauer
authors.forename: J
authors.initials: J
authors.lastname: Wanders
authors.forename: R S
authors.initials: RS
authors.lastname: Kaplan
authors.forename: L
authors.initials: L
authors.lastname: Rubinstein
authors.forename: J
authors.initials: J
authors.lastname: Verweij
authors.forename: M
authors.initials: M
authors.lastname: Van Glabbeke
authors.forename: A T
authors.initials: AT
authors.lastname: van Oosterom
authors.forename: M C
authors.initials: MC
authors.lastname: Christian
authors.forename: S G
authors.initials: SG
authors.lastname: Gwyther
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D004724:Endoscopy; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology; D017063:Outcome Assessment, Health Care / Q000379:methods*; D011859:Radiography; D012189:Retrospective Studies; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor